CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.

doi:10.1016/j.humimm.2013.04.031

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.

Human immunology - 1 Aug 2013

Zambra Francis Maria Báo, Biolchi Vanderlei, Brum Ilma Simoni, Chies José Artur Bogo

Abstract excerpt

Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are two chronic conditions, very common in aged men, that have been associated to inflammatory process. Chemokines and their receptors are recognized as critical mediators of inflammatory responses, they regulate immune cell migration and are implicated in tumor pathogenesis. The impact of two chemokine receptor gene polymorphisms, CCR2-64I (rs1799864)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Haplotypes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Grading

Share to Neoplasm Staging

Share to Odds Ratio

Share to Prostatic Hyperplasia

Share to Prostatic Neoplasms

Share to Receptors, CCR2

Share to Receptors, CCR5

Source

Open in PubMed

Identifiers

PMID: 23632061
DOI: 10.1016/j.humimm.2013.04.031

Genes

CCR2
CCR5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.PMID 23632061Read ↗

Association between circulating inflammatory proteins and benign prostatic disease: a Mendelian randomization study.Semantic proximity Read ↗

A genetic study to identify pathogenic mechanisms and drug targets for benign prostatic hyperplasia: a multi-omics Mendelian randomization study.Semantic proximity Read ↗

Associations of CYLD, JAK2 and TLR4 Genotypes with PSA Levels and Immunophenotype in Benign Prostatic Hyperplasia and Prostate Cancer.Semantic proximity Read ↗

Association of polymorphisms in MCP-1, CCR2, and CCR5 genes with the risk and clinicopathological characteristics of prostate cancer.Semantic proximity Read ↗

Nitric oxide synthase 2 gene polymorphisms are associated with prostatic volume in Korean men with benign prostatic hyperplasia.Semantic proximity Read ↗

Plasma metabolites as mediators in the relationship between inflammation-related proteins and benign prostatic hyperplasia: insights from mendelian randomization.Semantic proximity Read ↗

Benign prostatic hyperplasia genetic variants in Asians.Semantic proximity Read ↗

Genetic variants of chemokine CCL2 and chemokine receptor CCR2 genes and risk of prostate cancer.Semantic proximity Read ↗

Genetic variants in 2q31 and 5p15 are associated with aggressive benign prostatic hyperplasia in a Chinese population.Semantic proximity Read ↗

SLC25A37 is casually associated with the increased incidence of benign prostatic hyperplasiaSemantic proximity Read ↗

Genetic Polymorphisms of IFNG, IFNGR1, and Androgen Receptor and Chronic Prostatitis/Chronic Pelvic Pain Syndrome in a Chinese Han Population.Semantic proximity Read ↗

Cyclooxygenase 2 (rs2745557) Polymorphism and the Susceptibility to Benign Prostate Hyperplasia and Prostate Cancer in Egyptians.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.